RxDoctor Payments DataLook up a doctor →

Muhammad Khan, MD

Cardiovascular Disease · McKinney, TXNPI 1356334031

Payments from drug & device makers

$567,185in general payments, 2019–2025

Across 783 payments — averaging $724.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$106K
  • Vesper Medical$70K
  • Surmodics, Inc.$60K
  • Janssen Research & Development, LLC$59K
  • Endologix LLC$53K
  • Cordis US CORP.$47K
  • plus $172K from 43 others
$97,315in research payments, 2019–2025

Across 30 payments — averaging $3243.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$70K
  • Boston Scientific$18K
  • Vifor (international) Ltd.$7K
  • Cordis US CORP.$1K
  • Eli Lilly$974

What the payments were for

  • Speaking & faculty fees$1,80015%
  • Travel & lodging$3,80931%
  • Food & beverage$6,08149%
  • Education$2982%
  • Other$3893%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$567,185 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$643,113
Medicare patients
459
Services billed
7,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban309$381,456
EntrestoSacubitril/Valsartan79$90,704
Repatha SureclickEvolocumab37$44,061
VerquvoVericiguat18$24,247
Ranolazine ErRanolazine52$6,229
SotalolSotalol Hcl245$6,203
Metoprolol Succinate358$4,416
Nebivolol Hcl44$3,696
Losartan Potassium273$3,156
Propafenone Hcl ErPropafenone Hcl18$3,101
ClopidogrelClopidogrel Bisulfate328$3,036
Amiodarone Hcl54$2,841
Carvedilol291$2,289
Cilostazol78$2,239
Flecainide Acetate66$2,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18,988$381,456309 claims
NovartisEntresto$29,839$90,70479 claims
MerckVerquvo$857$24,24718 claims
Kowa Pharmaceuticals America, Inc.Bystolic$13$2,12912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →